Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Intrexon
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Intrexon
-
Prikvačeni tweet
#Precigen completes series of transactions to solidify healthcare focus. Name changes to@Precigen from@Intrexon and ticker symbol to@Nasdaq:$PGEN#Maryland#biopharma#GeneTherapy#CellTherapy#Immunotherapy https://prn.to/2SbVCiI pic.twitter.com/WAtE8eUz2H
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Triple-Gene to highlight its investigational
#genetherapy in Phase 1 for treatment of#heartfailure at#BiotechShowcase TODAY January 15th at 11:30am PT in Franciscan B at the Hilton San Francisco Union Square$XON#Precigen#cardiovasculardisease#JPMHC20#JPM2020#JPMorgan2020pic.twitter.com/QkvSDJXSYy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#JPMHC20? Listen to Dr. Helen Sabzevari, President & CEO of@Precigen, at 5pm PT in California West present on#Precigen progress and 2020 look ahead OR watch live webcast here: http://ow.ly/2ndc50xVC11$XON#JPM2020#JPMorgan2020#GeneTherapy#CellTherapy#Immunotherapypic.twitter.com/7R0AOpVECr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
Join Dr. Helen Sabzevari, President and CEO of Precigen, at
#JPM20 for her presentation on Precigen’s progress and a 2020 look ahead.#GeneTherapy#CellTherapy#Immunotherapy#Biotech#Maryland$XON https://bit.ly/2QMuOWK pic.twitter.com/dKVxJGUkt4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Triple-Gene to highlight advantages of its multigenic approach for treatment of
#heartfailure at#BiotechShowcase on January 15th, 2020 at 11:30AM PT at the Hilton San Francisco Union Square. Read more here: http://ow.ly/Aof250xR5IF#cardiovasculardisease#genetherapy$XONpic.twitter.com/ftEX8ZHm1s
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.https://www.bizjournals.com/washington/news/2020/01/06/intrexon-will-take-the-name-of-its-subsidiary-that.html?ana=TRUEANTHEMTWT_WA&taid=5e13db2fb19b7e000192e7b5&utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
#Precigen receives first regulatory designation for PRGN-3006 UltraCAR-T#OrphanDrugDesignation#immunotherapy#biotech https://prn.to/2ZThUcc pic.twitter.com/4TuSU92eD3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$XON To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To@Precigen To Reflect Healthcare Focus. Read more here: http://ow.ly/z7hz50xLsQx#immunotherapy#genetherapy#Maryland#biotechHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
#Precigen’s Tim Chan to present preclinical data from PRGN-3006 UltraCAR-T at#ASH2019 in Orlando, FL#CellTherapy#AML#MDS#BloodCancer#Immunotherapy https://bit.ly/2KFJm78 pic.twitter.com/QvgFRl43ya
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
Dr. Helen Sabzevari, President of
#Precigen, will speak at the upcoming World Vaccine & Immunotherapy Congress in San Francisco. Join us! https://bit.ly/2OFw2C3#immunotherapy#UltraCAR-T#oncology#CellTherapy#MarylandInnovates$XONpic.twitter.com/bDdqoduZwk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
Great news from our partners at
#Oragenics! Enrollment is now complete for their phase 2 clinical trial of AG013 for#oralmucositis. AG013 is an ActoBio Therapeutics Inc. candidate created on our#ActoBiotics® platform and licensed to Oragenics. More: http://actobio.com pic.twitter.com/PJ0V9inbEX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$XON subsidiary Triple-Gene presented preliminary phase 1 trial data of investigational multigenic therapeutic candidate INXN 4001 for treatment of#heartfailure at#AHA19. Discover more: http://ow.ly/M0x850xdDMp and http://ow.ly/l2AY50xdDMq#cardiovasculardisease#genetherapyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Discover more about Triple-Gene’s approach to address
#heartfailure:@physicianswkly highlights “The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure” http://ow.ly/OKbl50xc7WO$XON#cardiovasculardisease#genetherapyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Intrexon Reports Third Quarter Financial Results: http://ow.ly/I12g50x8EMd .
@Precigen to host conference call today at 11am ET to provide Precigen business and pipeline updates. Register for call here: http://ow.ly/uNn050x8EMb$XON#immunotherapy#genetherapy#celltherapyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Intrexon subsidiary Triple-Gene announces completion of dosing in Phase 1 trial of INXN-4001, first multigenic investigational
#genetherapy candidate for treatment of#heartfailure. Learn more here: http://ow.ly/rDyV50x4Cwt$XON#cardiovasculardiseasepic.twitter.com/gbN9EbxT8V
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$XON to Announce Third Quarter Financial Results on Nov 12th.@Precigen to host conference call that day at 11am ET to provide Precigen business and pipeline updates. To learn more and register, click here: http://ow.ly/Lw4750x1N4Q#immunotherapy#genetherapy#celltherapypic.twitter.com/q32MzSmuXQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
intrexon proslijedio/la je Tweet
Darling Ingredients and
@enviroflight help feed the world. 'Bugging' to know how? Find out: https://www.darlingii.com/drpam/feed#givingnatureasecondlife#innovativeproteins#protein#BSFpic.twitter.com/4ZN2IgUfQm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#BIOInvestorForum? Don’t miss#ActoBio Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform today Wednesday October 23 @ 9:15 AM PT. Read more: http://actobio.com or follow us on LinkedIn or Twitter@ActobioT#bif19#biotechpic.twitter.com/KF8zE57d8A
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#SynBioBeta? Don't miss#ActoBio Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: http://www.actobio.com or follow on Twitter@ActobioT or LinkedIn.#actobiotics#healthcare#biotechpic.twitter.com/CuLsXpxme1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
David Witte formerly of
@IHSMarkit to lead MBP Titan LLC, standalone subsidiary company of Intrexon comprising Intrexon’s#Methane#Bioconversion Platform. Discover more: http://ow.ly/3ewV50wrZUP .$XON#energy#bioengineering#betterDNApic.twitter.com/tohCCG1k9Q
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.